DNMT3A and thymoma: The prevalence was 62% in TCs and 13% in thymomas, with recurrent mutations in BAP1, BRCA2, CDKN2A, CYLD, DNMT3A, HRAS, KIT, SETD2, SMARCA4, TET2, and TP53 [23].